MSD has today confirmed that its
Zerbaxa (ceftolozane/tazobactam)
has been registered by the
Therapeutic Goods Administration
for the treatment of common
and problematic gram-negative
pathogens.
It’s the first new antibiotic
registered in Australia in almost
ten years for the treatment of
gram-negative pathogens, and
is approved for use in hospitals
for the treatment of complicated
intra-abdominal infections in
combination with metronidazole,
and complicated urinary tract
infections, including pyelonephritis.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Nov 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.